Steve Schonfeld’s Prelude Therapeutics PRLD Stock Holding History

Steve Schonfeld’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-18,000	Closed	-$94K	–	3121
2022 Q2	$94K	Buy	+18,000	New	+$91.6K	﹤0.01%	2158

Other funds holding PRLD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Steve Schonfeld's PRLD Position: Q3 2022 in Review

Steve Schonfeld sold out of Prelude Therapeutics (PRLD) in Q3 2022, closing a stake of 18,000 shares — an estimated $94K sold.

Steve Schonfeld first reported a position in PRLD in Q2 2022 and held it in 1 quarter. The position peaked at $94K in Q2 2022. 53 funds tracked by Wall St. Rank hold PRLD as of Q3 2022.

Steve Schonfeld reported no remaining Prelude Therapeutics position as of Q3 2022 after selling out during the quarter.
Steve Schonfeld sold 18,000 Prelude Therapeutics shares in Q3 2022, an estimated $94K.
Steve Schonfeld first reported a position in Prelude Therapeutics in Q2 2022 and held it in 1 quarter.
Steve Schonfeld's Prelude Therapeutics position peaked at $94K in Q2 2022.
53 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q3 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.